Please join us during our Community Webinar Series on April 17th as we welcome the team from Dyne Therapeutics to speak on updates to the DELIVER trial of DYNE-251 in males with Duchenne mutations amenable to exon 51 skipping.
Clinical Impact of FORCETM Platform in Duchenne
April 17, 2025 | 1pm ET| Zoom